Sanofi: Dupixent authorised to treat atopic dermatitis.
(CercleFinance.com) - Sanofi and Regeneron have announced that the European Commission has granted marketing authorisation (AMM) to Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic treatment.
As a form of eczema, moderate-to-severe atopic dermatitis is characterised by skin rashes on almost the whole body and may be accompanied by intense and persistent itching, dry, cracked and red skin, covered with excoriations which end up oozing and bleeding.
Following this marketing authorisation, Sanofi and Regeneron will work together with the relevant local authorities to make Dupixent available to patients who need it in European countries.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
As a form of eczema, moderate-to-severe atopic dermatitis is characterised by skin rashes on almost the whole body and may be accompanied by intense and persistent itching, dry, cracked and red skin, covered with excoriations which end up oozing and bleeding.
Following this marketing authorisation, Sanofi and Regeneron will work together with the relevant local authorities to make Dupixent available to patients who need it in European countries.
Copyright (c) 2017 CercleFinance.com. All rights reserved.